Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib

Nintedanib is an oral, small-molecule tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis and patients with advanced non-small cell cancer of adenocarcinoma tumour histology. Nintedanib competitively binds to the kinase domains of vascular endothelial growth factor...

Descripción completa

Detalles Bibliográficos
Autores principales: Wind, Sven, Schmid, Ulrike, Freiwald, Matthias, Marzin, Kristell, Lotz, Ralf, Ebner, Thomas, Stopfer, Peter, Dallinger, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719436/
https://www.ncbi.nlm.nih.gov/pubmed/31016670
http://dx.doi.org/10.1007/s40262-019-00766-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719436/
https://www.ncbi.nlm.nih.gov/pubmed/31016670
http://dx.doi.org/10.1007/s40262-019-00766-0

Ejemplares similares